Among 194 patients with stage IA-IIA NSCLC deemed high risk for recurrence by the assay, 2-year disease-free survival was 96% vs 79% in patients randomly assigned to adjuvant chemotherapy vs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results